SCHEMBL347764

SCHEMBL347764

CNCCNCCNCCNC

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 2/20 0.39
PRMT6 Q96LA8 2/20 0.39
PRMT8 Q9NR22 2/20 0.39
PRMT3 O60678 1/20 0.39
PRMT1 Q99873 1/20 0.39
LMNA P02545 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
ALDH1A1 P00352 2/20 0.38
CA12 O43570 2/20 0.38
CA6 P23280 2/20 0.38
CA7 P43166 2/20 0.38
CA9 Q16790 2/20 0.38
CA14 Q9ULX7 2/20 0.38
CA5B Q9Y2D0 2/20 0.38
CA1 P00915 1/20 0.38
CA2 P00918 1/20 0.38
CA3 P07451 1/20 0.38
ALOX15 P16050 1/20 0.38
CA4 P22748 1/20 0.38
CA5A P35218 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6131298 1.00 CARM1 (0.39) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL341303 1.00
SCHEMBL16948506 1.00 CARM1 (0.39) CARM1PRMT6PRMT8PRMT3PRMT1
Hydrochloric Acid SCHEMBL23478121 0.96 KDM4E (0.41) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL18608790 0.89 CYP2C19 (0.50) LMNATDP1ALDH1A1CA12CA6
SCHEMBL5173879 0.86
SCHEMBL18870232 0.86 EPHX1 (0.50) LMNATDP1ALDH1A1CA12CA6
SCHEMBL21003492 0.86 CYP2C19 (0.56) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL18372444 0.86 EPHX1 (0.43) CARM1PRMT6PRMT8PRMT3PRMT1
SCHEMBL16342225 0.86 EPHX1 (0.43) CARM1PRMT6PRMT8PRMT3PRMT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0058505-B1 PREPARATION OF ESTERS CONTAINING AN ALPHA-CYANO GROUP IN THE ALCOHOL PORTION OF THE ESTERS FMC Corporation (US) 1985-05-29 EP claimed
US-11772085-B2 Far superior oxidation catalysts based on macrocyclic compounds CARNEGIE MELLON UNIVERSITY (US) 2023-10-03 US disclosed
WO-2023130021-A1 CHEMICALLY MODIFIED OLIGONUCLEOTIDES WITH IMPROVED DELIVERY PROPERTIES PHIO PHARMACEUTICALS CORP. (US) 2023-07-06 WO disclosed
WO-2023022926-A1 NANOPARTICLE COMPOSITIONS CONTAINING SUGAR FUNCTIONALIZED NUCLEIC ACID CARRIERS TIBA BIOTECH LLC (US) 2023-02-23 WO disclosed
US-11090395-B2 Composition for cross talk between estrogen receptors and cannabinoid receptors SeeCure Taiwan Co., Ltd. (TW) 2021-08-17 US disclosed
EP-3862005-A1 NUCLEIC ACID MOLECULES TARGETING SUPEROXIDE DISMUTASE 1 (SOD1) Phio Pharmaceuticals Corp. (US) 2021-08-11 EP disclosed
US-11078413-B2 Organic-inorganic hybrid perovskites, devices, and methods FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 2021-08-03 US disclosed
US-20210196655-A1 COMPOSITION FOR CROSS TALK BETWEEN ESTROGEN RECEPTORS AND CANNABINOID RECEPTORS SeeCure Taiwan Co., Ltd. (TW) 2021-07-01 US disclosed
EP-3512865-B1 ESTERS OF 3-POLYAMINE DERIVATIVES OF BILE ACIDS FOR THE TREATMENT OF INFECTIONS VIRBAC (FR) 2021-05-05 EP disclosed
US-20210032273-A1 Methods of Making Metal Halide Perovskites FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. 2021-02-04 US disclosed
US-20120016147-A1 METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-01-19 US disclosed
US-8048982-B2 Method for producing aromatic compound polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2011-11-01 US disclosed
WO-2011107512-A1 THE USE OF LINEAR TRIETHYLENTETRAMINE AS CURING AGENT FOR EPOXY RESINS BASF SE (DE) 2011-09-09 WO disclosed
US-20110052673-A1 THERAPEUTIC COMPOSITIONS SHIRE HUMAN GENETIC THERAPIES, INC. 2011-03-03 US disclosed
WO-2010146009-A1 METHYL-SUBSTITUTED TETA COMPOUNDS BASF SE (DE) 2010-12-23 WO disclosed
EP-2241548-A1 Vanadium di-nuclear complex Sumitomo Chemical Company, Limited (JP) 2010-10-20 EP disclosed
EP-2241547-A1 Method for producing aromatic compound polymer Sumitomo Chemical Company, Limited (JP) 2010-10-20 EP disclosed
US-20090018309-A1 Method for Producing Aromatic Compound Polymer SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-01-15 US disclosed
US-7354568-B1 Magnetic resonance imaging agents for the detection of physiological agents CALIFORNIA INSTITUTE OF TECHNOLOGY (US) 2008-04-08 US disclosed
EP-1767560-A1 METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER Sumitomo Chemical Company, Limited (JP) 2007-03-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11090395-B2 Composition for cross talk between estrogen receptors and cannabinoid receptors GPER1, ESR1, CNR1 CARM1 4107/4885PRMT6 3909/4885PRMT8 2480/4885
US-20090018309-A1 Method for Producing Aromatic Compound Polymer PAH, MAOA, AHR CARM1 1467/4885PRMT6 1699/4885PRMT8 899/4885
US-20210032273-A1 Methods of Making Metal Halide Perovskites SOD1, HCN4, KCND2 CARM1 1238/4885PRMT6 1211/4885PRMT8 2707/4885
US-11772085-B2 Far superior oxidation catalysts based on macrocyclic compounds SOD1, ME3, ME2 CARM1 2303/4885PRMT6 1831/4885PRMT8 1265/4885
US-11078413-B2 Organic-inorganic hybrid perovskites, devices, and methods TYR, HCN4, BMI1 CARM1 3089/4885PRMT6 3642/4885PRMT8 4078/4885
US-20110052673-A1 THERAPEUTIC COMPOSITIONS PHOSPHO1, SGMS1, APOB CARM1 911/4885PRMT6 211/4885PRMT8 641/4885
US-20120016147-A1 METHOD FOR PRODUCING AROMATIC COMPOUND POLYMER PAH, MAOA, AHR CARM1 1534/4885PRMT6 1727/4885PRMT8 942/4885
US-20210196655-A1 COMPOSITION FOR CROSS TALK BETWEEN ESTROGEN RECEPTORS AND CANNABINOID RECEPTORS GPER1, ESR1, CNR1 CARM1 4107/4885PRMT6 3909/4885PRMT8 2480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.